CYTH Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 29.78%

Insider Buying (Last 12 Months): $5,000,000.00

Insider Selling (Last 12 Months): $0.00

Cyclo Therapeutics Insider Trading History Chart

Cyclo Therapeutics Share Price & Price History

^$1.15

▲ +0.03 (2.68%)

As of 07/26/2024 01:00 AM ET

Days: 30 | 90 | 365

J.P. Morgan’s DIRE Warning

From Behind the Markets | Ad

When the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."

Click here to see why Wall Street is in PANIC mode >>>

Cyclo Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/1/2023	Rafael Holdings, Inc.	Major Shareholder	Buy	4,000,000	$1.25	$5,000,000.00	6,514,970
4/20/2023	Jeffrey Tate	COO	Buy	29,941	$0.71	$21,258.11	62,101
4/20/2023	Markus Sieger	Director	Buy	59,881	$0.71	$42,515.51	161,051
4/20/2023	N. Scott Fine	CEO	Buy	299,402	$0.71	$212,575.42	444,402
9/21/2022	Francis Patrick Ostronic	Director	Buy	5,000	$1.76	$8,800.00	150,687
9/21/2022	Francis Patrick Ostronic	Director	Buy	5,000	$1.76	$8,800.00	150,687
5/20/2022	Francis Patrick Ostronic	Director	Buy	5,000	$2.04	$10,200.00	138,525
5/16/2022	Jeffrey Tate	COO	Buy	3,000	$2.12	$6,360.00	32,160
4/28/2022	Jeffrey Tate	COO	Buy	635	$2.50	$1,587.50	27,795
3/29/2022	Markus Sieger	Director	Buy	10,000	$2.73	$27,300.00
2/7/2022	N. Scott Fine	CEO	Buy	10,334	$3.58	$36,995.72
1/24/2022	Francis Patrick Ostronic	Director	Buy	2,000	$3.75	$7,500.00
1/19/2022	Francis Patrick Ostronic	Director	Buy	1,132	$4.00	$4,528.00
1/19/2022	N. Scott Fine	CEO	Buy	5,000	$3.89	$19,450.00
1/14/2022	Francis Patrick Ostronic	Director	Buy	2,137	$4.00	$8,548.00
12/15/2021	Francis Patrick Ostronic	Director	Buy	3,000	$3.90	$11,700.00
12/15/2021	N. Scott Fine	CEO	Buy	5,000	$3.89	$19,450.00
12/3/2021	Francis Patrick Ostronic	Director	Buy	864	$4.75	$4,104.00
12/2/2021	Sharon Hemond Hrynkow	Insider	Buy	1,000	$4.98	$4,980.00
12/1/2021	Francis Patrick Ostronic	Director	Buy	5,000	$5.00	$25,000.00
11/19/2021	Francis Patrick Ostronic	Director	Buy	10,652	$5.25	$55,923.00
11/19/2021	N. Scott Fine	CEO	Buy	5,000	$5.25	$26,250.00
10/29/2021	Francis Patrick Ostronic	Director	Buy	1,000	$5.90	$5,900.00
9/15/2021	N. Scott Fine	CEO	Buy	5,000	$6.35	$31,750.00	114,666

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

From Traders Agency | Ad

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

SEC Filings (Institutional Ownership Changes) for Cyclo Therapeutics (NASDAQ:CYTH)

68.55% of Cyclo Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Cyclo Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/15/2024	Founders Fund V Management LLC	480,708	$0.76M	80.8%	N/A	2.115%
2/15/2024	Founders Fund VI Management LLC	110,023	$0.18M	1.4%	N/A	0.484%
11/9/2021	BlackRock Inc.	13,134	$88K	0.0%	+21.1%	0.204%
8/16/2021	State Street Corp	44,700	$0.46M	0.0%	N/A	0.703%
8/13/2021	Geode Capital Management LLC	42,577	$0.44M	0.0%	+133.2%	0.670%
8/13/2021	Vanguard Group Inc.	151,540	$1.55M	0.0%	+350.4%	2.383%
5/12/2021	Geode Capital Management LLC	18,257	$0.15M	0.0%	N/A	0.287%
3/26/2021	Susquehanna International Group LLP	15,656	$68K	0.0%	N/A	0.249%
2/17/2021	Jane Street Group LLC	27,892	$0.12M	0.0%	N/A	1.641%
2/17/2021	Worth Venture Partners LLC	88,690	$0.39M	0.3%	N/A	5.217%
2/16/2021	Armistice Capital LLC	100,000	$0.44M	0.0%	N/A	5.882%

Data available starting January 2016

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

Today's Range

Now: $1.15

$1.12

$1.15

50 Day Range

MA: $1.25

$1.12

$1.42

52 Week Range

Now: $1.15

$0.89

$2.12

Volume

12,289 shs

Average Volume

71,633 shs

Market Capitalization

$32.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Cyclo Therapeutics?: Cyclo Therapeutics' top insider investors include:
Rafael Holdings, Inc (Major Shareholder)
N Scott Fine (CEO)
Markus Sieger (Director)
Francis Patrick Ostronic (Director)
Jeffrey Tate (COO)
Learn More about top insider investors at Cyclo Therapeutics.